logo
Hassett says White House probing Fed renovation costs, authority to fire Powell

Hassett says White House probing Fed renovation costs, authority to fire Powell

Reuters13-07-2025
WASHINGTON, July 13 (Reuters) - U.S. President Donald Trump has the authority to fire Federal Reserve Chair Jerome Powell for cause if evidence supports that, White House economic adviser Kevin Hassett said on Sunday, adding that the Fed "has a lot to answer for" on renovation cost overruns at its Washington headquarters.
Hassett told ABC's "This Week" program that any decision by Trump to try to fire Powell over what the Trump administration calls a $700 million cost overrun "is going to depend a lot on the answers that we get to the questions that Russ Vought sent to the Fed."
Vought, the White House budget director, last week slammed Powell over an "ostentatious overhaul" of the Fed's buildings and answers to a series of questions about the $2.5 billion project. In a posting on X, he compared the project to France's Palace of Versailles, with rooftop gardens, water features and "premium marble."
Hassett's comments confirm that the Trump administration is actively exploring the renovation costs and Powell's testimony about the project as a possible avenue to try to fire the Fed chief well before his term as chair ends in May 2026.
Trump has repeatedly called for Powell's resignation for failing to lower interest rates since Trump returned to office in January.
Asked if Trump had the authority to fire Powell, Hassett, whose name has emerged as a potential candidate take over the Fed chair job, said: "That's a thing that's being looked into, but certainly if there's cause, he does."
Republican Representative French Hill, who chairs the powerful House Financial Services Committee, said Trump did not have the authority to fire the Fed chair, but Congress would continue to provide strong oversight of the central bank.
"Just because Congress created the Fed and that we believe that it should be independent in the setting of monetary policy, it doesn't mean that it's immune from criticism," Hill told CBS' Face the Nation. "Every president since World War Two has had choice words for the Fed chair when they've not been in sync with the direction of the president."
Powell in June denied that the Fed was spending money excessively on renovations, telling senators that the almost 90-year-old headquarters "was not really safe, and it was not waterproof" while acknowledging cost overruns.
The Fed has said that the project, which includes upgrades to an adjacent building, will consolidate staff into a single campus and reduce off-site lease costs. However, a Fed Inspector General report, opens new tabacknowledged in February that costs had risen to $2.4 billion from an estimate of $1.9 billion two years earlier.
"There are no new water features, there's no beehives, and there's no roof terrace gardens," Powell said in response to allegations from Republican senators.
Separately on Sunday, Kevin Warsh, a former Fed Board of Governors member who is considered a potential candidate to replace Powell, said the U.S. central bank needs "regime change" that goes beyond the chair position.
"The Fed has lost its way. It's lost its way in supervision, it's lost its way in monetary policy," Warsh said in a Sunday interview on Fox's Sunday Morning Futures program.
Asked whether he would accept a position on the Board of Governors when an expected vacancy opens in January, Warsh said "it's a great job" and that the institution needs major reform.
"We need regime change at the Fed, and that's not just about the chairman. It's about a whole range of people, it's about changing their mindset and their models, and frankly it's about breaking some heads, because the way they've been doing business is not working."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

JD Vance hits the road to sell Trump's ‘Big, Beautiful Bill'
JD Vance hits the road to sell Trump's ‘Big, Beautiful Bill'

The Independent

time3 minutes ago

  • The Independent

JD Vance hits the road to sell Trump's ‘Big, Beautiful Bill'

Vice President JD Vance will visit his home state of Ohio on Monday to continue promoting the GOP's sweeping tax-and-border bill. His office confirmed he will be in Canton, Ohio, to discuss the bill's 'benefits for hardworking American families and businesses'. While his aides offered little detail in advance about the visit, NBC News reported that his remarks will take place at a steel plant in Canton, located about 60 miles south of Cleveland. The visit marks Vance's second trip this month to sell the legislative package, filled with a hodgepodge of conservative priorities that Republicans have dubbed the 'One Big, Beautiful Bill' as the vice president becomes its chief promoter on the road. In West Pittston, Pennsylvania, Vance told attendees at an industrial machine shop that they should be able to keep more of their pay in their pockets, highlighting the law's new tax deductions on overtime. Vance also discussed a new children's savings program called Trump Accounts and how the new law promotes energy extraction, while decrying Democrats for opposing the bill that keeps the current tax rates, which would have otherwise expired later this year. The legislation cleared the GOP-controlled Congress by the narrowest of margins, with Vance breaking a tie vote in the Senate for the package that also sets aside hundreds of billions of dollars for Trump's immigration agenda while slashing Medicaid and food stamps. The vice president is also stepping up his public relations blitz on the bill as the White House tries to deflect attention away from the growing controversy over Jeffrey Epstein. The disgraced financier killed himself, authorities say, in a New York jail cell in 2019 as he awaited trial on sex trafficking charges. Trump and his top allies stoked conspiracy theories about Epstein's death before Trump returned to the White House and are now reckoning with the consequences of a Justice Department announcement earlier this month that Epstein did indeed die by suicide and that no further documents about the case would be released. Questions about the case continued to dog Trump in Scotland, where he on Sunday announced a framework trade deal with the European Union. Asked about the timing of the trade announcement and the Epstein case and whether it was correlated, Trump responded: 'You've got to be kidding with that.' 'No, had nothing to do with it,' Trump told the reporter. 'Only you would think that.' The White House sees the new law as a clear political boon, sending Vance to promote it in swing congressional districts that will determine whether Republicans retain their House majority next year. The northeastern Pennsylvania stop is in the district represented by Republican Rep. Rob Bresnahan, a first-term lawmaker who knocked off a six-time Democratic incumbent last fall. On Monday, Vance will be in the district of Democratic Rep. Emilia Sykes, who is a top target for the National Republican Congressional Committee this cycle. Polls before the bill's passage showed that it largely remained unpopular, although the public approves of some individual provisions, such as increasing the child tax credit and allowing workers to deduct more of their tips on taxes.

Thailand and Cambodia agree immediate ceasefire following months of tension
Thailand and Cambodia agree immediate ceasefire following months of tension

The Independent

time3 minutes ago

  • The Independent

Thailand and Cambodia agree immediate ceasefire following months of tension

Thailand and Cambodia have agreed to an immediate and unconditional ceasefire to resolve deadly border clashes, effective from midnight on 28 July. The agreement was reached during talks in Kuala Lumpur, chaired by Malaysian Prime Minister Anwar Ibrahim, who leads the ASEAN regional bloc. The conflict, which had entered its fifth day, resulted in at least 35 fatalities and displaced over 260,000 people on both sides of the frontier. Fighting escalated after a land mine explosion wounded Thai soldiers, with both nations blaming each other for initiating the hostilities. The peace talks followed international pressure, including from US President Donald Trump, and concerns expressed by ASEAN foreign ministers.

Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Weight-loss jab Wegovy sees another prescription boost after ban on copycats

The Independent

time3 minutes ago

  • The Independent

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo Nordisk's weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors. Since the US Food and Drug Administration (FDA) implemented a ban on 'compounded' versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts. The overall increase in Wegovy prescriptions is also narrowing the market lead held by Eli Lilly and Co's rival drug, Zepbound. While Zepbound prescriptions outpaced Wegovy by nearly 175,000 in the US during the week ending 23 May, this gap had reduced to around 133,000 by 18 July. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. Capturing more of the patients who had turned to compounded drugs is key to meeting targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store